<DOC>
	<DOCNO>NCT00042965</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine capecitabine gemcitabine treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Capecitabine Gemcitabine Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient metastatic renal cell carcinoma treat gemcitabine capecitabine . - Determine duration overall progression-free survival patient treat regimen . - Determine toxicity regimen patient .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Clinically confirm metastatic disease ( histologic documentation metastatic disease require ) Sarcomatoid renal cell carcinoma allow No pure sarcomas No collect duct ( duct Bellini ) tumor , oncocytomas , transitional cell tumor Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan Nonmeasurable lesion include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Patients know brain metastasis eligible undergone prior surgical resection and/or cranial irradiation , currently require steroid anticonvulsant , progressive disease CT scan MRI least 4 week completion radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal Renal Creatinine clearance least 30 mL/min Cardiac No clinically significant cardiac disease No congestive heart failure No symptomatic coronary artery disease No cardiac arrhythmias well control medication No myocardial infarction within past 12 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study No prior severe reaction fluoropyrimidine therapy know sensitivity fluorouracil No malabsorption syndrome lack physical integrity upper gastrointestinal tract would preclude absorption capecitabine PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy recover No prior gemcitabine No prior fluoropyrimidines ( e.g. , fluorouracil , floxuridine , capecitabine , fluorouraciluracil ) No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 4 week since prior megestrol No concurrent hormone ( e.g. , megestrol ) except steroid adrenal failure , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy recover Prior radiotherapy lesion may produce disability ( e.g. , unstable femur ) allow No concurrent palliative radiotherapy Surgery See Disease Characteristics At least 4 week since prior major surgery recover Other Any number prior regimen allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>